Dacuronium bromide

Dacuronium bromide
Dacuronium_bromide.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Dacuronium bromide is a non-depolarizing neuromuscular blocking agent used in anesthesia to induce muscle relaxation during surgery or mechanical ventilation. It is part of the aminosteroid class of neuromuscular blockers.

Mechanism of Action

Dacuronium bromide works by competitively inhibiting the action of acetylcholine at the neuromuscular junction. It binds to the nicotinic acetylcholine receptor on the motor end plate, preventing acetylcholine from binding and triggering muscle contraction. This results in muscle paralysis, which is reversible with the administration of acetylcholinesterase inhibitors such as neostigmine.

Pharmacokinetics

Dacuronium bromide is administered intravenously. It has a rapid onset of action, typically within 2 to 3 minutes, and a duration of action of approximately 30 to 60 minutes. The drug is metabolized in the liver and excreted primarily in the urine.

Clinical Use

Dacuronium bromide is used in various surgical procedures to facilitate endotracheal intubation and provide muscle relaxation. It is also used in the intensive care setting to facilitate mechanical ventilation in patients who require prolonged respiratory support.

Side Effects

Common side effects of dacuronium bromide include hypotension, tachycardia, and bronchospasm. Rarely, it may cause anaphylaxis or prolonged neuromuscular blockade, especially in patients with hepatic or renal impairment.

Contraindications

Dacuronium bromide is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is advised in patients with myasthenia gravis or other neuromuscular disorders.

Related pages

• Neuromuscular-blocking drug
• Anesthesia
• Acetylcholine
• Endotracheal intubation

• 
  Dacuronium bromide chemical structure